BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales

Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.

Competitive market
BioCryst's Orladeyo is gradually establishing its place in the competitive HAE space • Source: Shutterstock

BioCryst Pharmaceuticals, Inc.’s launch numbers for Orladeyo (berotralstat) have beat expectations, and the North Carolina-based firm says its drug – the first oral prophylaxis for hereditary angioedema (HAE) – is on track to eventually become a blockbuster, despite being the eighth HAE drug launched in the US. The product brought in $65.2m during the second quarter of 2022 and the firm increased its full-year sales projection from $250m to a range of $255m-$265m.

[Sidebar#SC146260]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip